How Will the Market React to Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Getting a Bearish Rating

Corbus Pharmaceuticals Holdings Inc (CRBP) stock is lower by 5.36% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Corbus Pharmaceuticals Holdings Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CRBP!

See Full CRBP Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CRBP Stock Today?

Corbus Pharmaceuticals Holdings Inc (CRBP) stock has risen 3.11% while the S&P 500 has fallen -0.36% as of 2:53 PM on Friday, Jan 14. CRBP has gained $0.02 from the previous closing price of $0.51 on volume of 546,969 shares. Over the past year the S&P 500 has gained 21.85% while CRBP has fallen -67.08%. CRBP lost -$0.40 per share in the over the last 12 months.

More About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Click Here to get the full Stock Report for Corbus Pharmaceuticals Holdings Inc stock.